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A B S T R A C T
Objective: To assess the effectiveness of single-dose rifampicin (SDR) after bacillus Calmette–Guérin
(BCG) vaccination in preventing leprosy in contacts.
Methods: This was a single-centre, cluster-randomized controlled trial at a leprosy control programme in
northwest Bangladesh. Participants were the 14 988 contacts of 1552 new leprosy patients who were
randomized into the SDR  arm (n = 7379) and the SDR + arm (n = 7609). In the intervention group, BCG
vaccination was followed by SDR 8–12 weeks later. In the control group, BCG vaccination only was given.
Follow-up was performed at 1 year and 2 years after intake. The main outcome measure was the
occurrence of leprosy.
Results: The incidence rate per 10 000 person-years at risk was 44 in the SDR  arm and 31 in the
SDR + arm at 1 year; the incidence rate was 34 in the SDR  arm and 41 in the SDR + arm at 2 years. There
was a statistically non-signiﬁcant (p = 0.148; 42%) reduction for paucibacillary (PB) leprosy in the SDR+
arm at 1 year. Of all new cases, 33.6% appeared within 8–12 weeks after BCG vaccination.
Conclusions: In the ﬁrst year, SDR after BCG vaccination reduced the incidence of PB leprosy among
contacts by 42%. This was a statistically non-signiﬁcant reduction due to the limited number of cases after
SDR was administered. To what extent SDR suppresses excess leprosy cases after BCG vaccination is
difﬁcult to establish because many cases appeared before the SDR intervention.
Trial registration: Netherlands Trial Register: NTR3087.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The global number of new leprosy cases has remained stable
over the last decade (Anonymous, 2017a), indicating that
transmission of Mycobacterium leprae, the causative agent of
leprosy, is ongoing in many endemic countries. The basic
intervention in leprosy control is multidrug therapy (MDT), but
this appears insufﬁcient to decrease new cases numbers and* Corresponding author at: Department of Public Health, Erasmus MC, University
Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
E-mail address: j.richardus@erasmusmc.nl (J.H. Richardus).
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https://doi.org/10.1016/j.ijid.2019.08.035
1201-9712/© 2019 The Authors. Published by Elsevier Ltd on behalf of International Soc
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).achieve the World Health Organization (WHO) target of reducing
the burden of leprosy (Anonymous, 2018).
Close contacts of untreated leprosy cases are exposed
considerably to M. leprae. Age of the contact, bacterial load of
the index patient, and close physical and genetic distance are
independent risk factors for the development of leprosy (Moet
et al., 2006). Household contacts of newly diagnosed patients have
a 10-fold higher risk of developing leprosy compared with the
general population (Moet et al., 2008a); for different categories of
neighbours and social contacts, this is three- to ﬁve-fold higher
(Moet et al., 2006; Moet et al., 2008a).
Many studies on immunoprophylaxis (vaccination) and che-
moprophylaxis aimed at preventing leprosy have focused primar-
ily on contacts of leprosy patients. Bacillus Calmette–Guérin (BCG)
vaccination is known as a vaccine against tuberculosis (TB) and isiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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scheme in many parts of the world. Moreover, BCG is also
recognized as protecting against leprosy (Merle et al., 2010; Setia
et al., 2006). Several vaccine trials using BCG have established its
protective effect against leprosy, often in combination with M.
leprae or related Mycobacterium vaccines (Merle et al., 2010; Fine
and Ponnighaus, 1988; Coppola et al., 2018; Kumar, 2017; Sharma
et al., 2005; Richardus and Oskam, 2015). Brazil has ofﬁcially
recommended BCG since the early 1970s for household contacts of
leprosy cases, as a booster to routine neonatal BCG vaccination
against TB. Since 1991, the Brazilian Ministry of Health has advised
two doses of BCG to be administered to household contacts. This
policy was assessed in a cohort study in Brazil (Duppre et al., 2008),
and showed 56% protection by a booster BCG vaccination. The risk
of tuberculoid leprosy during the initial months was high among
BCG-vaccinated contacts. Due to incomplete follow-up, the
increased risk of paucibacillary (PB) leprosy in the ﬁrst months
after BCG requires further substantiation.
Regarding chemoprophylaxis, a study in Bangladesh (the COLEP
trial) showed that a single dose of rifampicin (SDR) in contacts of
newly diagnosed leprosy patients reduced the overall incidence of
leprosy in the ﬁrst 2 years by 57% (Moet et al., 2008b).
Furthermore, this study showed that the effect of SDR depended
on the BCG status of the contact (Schuring et al., 2009): if the
contact had received BCG vaccination as part of a childhood
vaccination programme, the protective effect of SDR was 80%.
Contacts who received SDR without prior BCG vaccination had a
protective effect of 58%. Recently, the WHO has included SDR as a
recommendation in its guidelines for the diagnosis, treatment and
prevention of leprosy (Anonymous, 2017b).
Based on earlier studies investigating BCG vaccination and SDR
chemoprophylaxis in the prevention of leprosy among contacts, a
trial was initiated to assess the efﬁcacy of a combined strategy (the
MALTALEP trial). The main objective of this trial was to assess the
effectiveness of SDR given after BCG vaccination in preventing
leprosy in close contacts of patients with newly diagnosed leprosy.
More speciﬁcally, the aim was to determine whether possible
excess cases in the ﬁrst year after immunoprophylaxis, as observed
previously in Brazil (Duppre et al., 2008), could be prevented by
chemoprophylaxis.
Materials and methods
Trial design
The intervention was a cluster randomized controlled trial with
two treatment arms, to study the effectiveness of single-dose
rifampicin (SDR + arm) given after BCG vaccination in the preven-
tion of leprosy among contacts of newly diagnosed leprosy
patients, versus BCG vaccine alone (SDR  arm) (Figure 1). During
the initial contact survey, BCG was given to all eligible contacts,
followed by chemoprophylaxis with SDR 8–12 weeks later in those
contact groups randomized to receive this (FU1). Follow-up
examinations were performed at 1 year (FU2) and 2 years (FU3)
after receiving BCG. The three follow-up time points were used to
investigate whether contacts had developed leprosy (primary
outcome measure). Also, contacts were examined for adverse
events at the different follow-up points. Due to operational
difﬁculties caused by political instability in the country, it was not
always possible to provide SDR exactly 8 weeks after BCG, so the
range was broadened to 8–12 weeks after BCG.
Eligibility criteria for participants
Newly diagnosed leprosy patients were included who had been
diagnosed with leprosy according to the Rural Health Program(RHP) guidelines, which follow those of the National Leprosy
Control Programme (Anonymous, 1998; Anonymous, 2006). The
diagnosis of leprosy was made when at least one of the cardinal
signs was present: one or more skin lesions consistent with leprosy
and with deﬁnite sensory loss; thickened peripheral nerve(s); and
a positive skin smear result for acid-fast bacilli. Patients with
negative smear results and ﬁve or fewer skin lesions were grouped
as PB leprosy, and those with positive smear results or more than
ﬁve skin lesions were grouped as multibacillary (MB) leprosy,
according to the WHO treatment criteria. MDT was started
according to the national guidelines. Within 2 weeks after newly
diagnosed leprosy patients had received the second dose of MDT (4
weeks after the ﬁrst dose), a household survey was performed.
Contact groups were formed of around 10–15 persons for each
patient.
Exclusion criteria for patients and contacts are summarized in
the previously published methodology article (Richardus et al.,
2013). Only close contacts were included, i.e. household contacts
and next-door neighbours. Contacts were categorized according to
their physical and genetic distance to the index patient. For
physical distance, four categories were deﬁned based on the local
housing situation: shares a house and kitchen, shares a kitchen
only, shares a house but not a kitchen (together called household
contacts), and next-door neighbours. For genetic distance, two
groups were deﬁned: blood-related (parent, child, or sibling) and
not blood-related or unclear (all others). Written informed
consent was obtained from all patients and their contacts. For
those who were illiterate, a thumb print was obtained. For minors
under 16 years of age, the guardian’s additional consent was
obtained.
Study setting
The study was performed in the districts of Nilphamari,
Rangpur, Thakurgaon, and Panchagarh in the northwest of
Bangladesh. Patients entered the trial through the RHP of The
Leprosy Mission International, Bangladesh (TLMI,B), based at
the DBLM Hospital in Nilphamari, a referral hospital specialized
in the detection and treatment of leprosy. The population of the
four districts at the start of intake was around 7 000 000, and 800–
900 new leprosy patients were detected per year (Anonymous,
2011). The prevalence rate of HIV in adults aged 15 to 49 years in
Bangladesh in 2018 was <0.1 (UNAIDS).
Interventions
The BCG vaccine was applied by trained research assistants to
all included contacts (0.1 ml of BCG vaccine by intradermal
injection). Two different BCG strains were used in the trial (and
in routine neonatal vaccination in Bangladesh). The Indian vaccine
was used between 2011 and 2015 (Moscow strain 361) and
the Japanese vaccine in 2016 and 2017 (Tokyo strain 172). These
are freeze-dried glutamate BCG vaccines composed of 0.5 mg/
ampoule live bacteria of Calmette–Guérin (as approximately 70%
moist bacteria) and 2.0 mg/ampoule sodium glutamate (as a
stabilizer). The BCG vaccine was stored at the Government
Immunisation Programme facilities.
Rifampicin comes in capsules of 150 mg, and the dosage used
was the same as that recommended in the guidelines of the
National Leprosy Control Programme of Bangladesh and the RHP
(Table 1).
Outcomes
The primary outcome measure was the number of new leprosy
patients emerging from the contact groups. The proportions of new
Figure 1. Flow of participants through the trial (MALTALEP study).
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after 1 and 2 years.
Sample size
In the earlier COLEP trial (Moet et al., 2008b), the incidence rate
(IR) of leprosy among household contacts and direct neighbours
was found to be 40 per 10 000 per year in the untreated group over
the ﬁrst 2 years. It was hypothesized that in contacts receiving BCG
only, this number would be similar in the ﬁrst year or possibly
slightly increased. Also based on the previous trial, a 50% reductionTable 1
Dosage of rifampicin chemoprophylaxis according to age and body weight.
Age/weight Dose of rifampicin
Adult >35 kg 600 mg
Adult <35 kg 450 mg
Child 10–14 years 450 mg
Child 5–9 years 300 mgthrough the SDR intervention was expected (IR of 2 per 1000).
Based on these ﬁgures (with two-sided α = 0.05, power = 0.80), a
total of about 10 000 contacts would be necessary in each group to
detect reliably the expected protective effect of the BCG plus SDR
combination of 50%, considering an expected 10% loss to follow-up
of contacts.
Intake took place between July 2012 and January 2017. The
intake took longer than originally planned, since the required
number of contacts according to the power calculation had not yet
been reached. Nevertheless, it was necessary to end recruitment in
2017 for budgetary reasons. Follow-up after 2 years was completed
in January 2019.
Interim analyses and stopping guidelines
As the trial was not blinded, it was possible to assess the
outcomes during the study. This was done annually. The main
stopping criterion was the occurrence of more serious adverse
reactions to BCG vaccination among contacts than described in the
literature.
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proportion of healthy contacts of patients (0.4%) presenting with
PB leprosy within 12 weeks after receiving the BCG vaccination
(i.e., in the timeframe before SDR was given) (Richardus et al.,
2015). Since it was too early in the trial to draw deﬁnite conclusions
about this ﬁnding, the study was continued according to the
protocol.
Randomization
Each contact group was allocated randomly to one of the two
study arms (arm 1: BCG only; arm 2: BCG plus SDR) by means of a
computer-generated random sequence with a 1:1 ratio for each
arm. A block size of 10 was used. A randomization table was
created with 2000 sequential study numbers (one for each contact
group). Each study number received a random number generated
in MS Excel and this was ﬁxed. The table was then sorted by block
number and random number. Within each block of 10 study
numbers, the highest ﬁve random numbers were assigned SDR, the
lowest ﬁve were assigned no SDR. The allocation was generated by
the database manager (RF); participants were enrolled by ﬁeld
staff. On inclusion of a new index patient, the local database
manager (KK) entered the index into the database. Randomization
into an arm of the trial was achieved by automatically assigning
each next study number to the contact group, thus assigning the
pre-allocated randomization group of the study number.
Blinding
Blinding was not possible because there were no placebo
capsules of rifampicin available and we were not able to locate any
company that could produce these especially for this trial.
Statistical methods
For the calculation of the primary outcome measure, we started
at FU1, the time when SDR was provided in the treatment arm (SDR
+) of the trial. Contacts who developed leprosy after BCG
vaccination, but before FU1, were not included in the calculation
of the primary outcome measure. IRs per 10 000 person-years at
risk (PYAR) were calculated for year 1 (FU2) and year 2 (FU3) of
follow-up. The numbers at risk were calculated by adding the
number of new cases of leprosy to the number of contacts without
leprosy at the same follow-up moment. The probability of
developing leprosy at 2 years was converted to the IR assuming
a constant hazard during the period (rate = log(1  leprosy/total)/
2). To obtain conﬁdence intervals (CI), we applied the standard
errors of the probability of developing leprosy (sqrt(1/leprosy + 1/
no leprosy)) around the log(rate). Additionally, the number needed
to treat for BCG + SDR was estimated. A signiﬁcance level of 5% was
used in all tests.
The statistical analyses were done using SAS 9.4. Techniques for
the analysis of survey samples were used to account for clustering
at the level of the index patient in the sample. Bivariate
associations were investigated using proc surveyfreq and the
Rao–Scott Chi-square test instead of the Pearson Chi-square test.
Additional analyses
The effectiveness of BCG alone and BCG with SDR was
investigated in different subgroups and odds ratios (OR) were
reported, which are comparable to relative risks due to the low
prevalence of leprosy. Additionally, the number needed to treat
(NNT) per subgroup of contacts was reported. Clustering was
accounted for through the proc survey logistic instead of ordinary
logistic regression.Results
A total of 1552 index patients were included, of whom 1077
(70%) were PB leprosy patients and 475 (30%) were MB patients.
The intake of PB leprosy index patients was intentionally ended
when around 1000 had been included, to ensure an intake of at
least 300 MB patients. The number of participants in each arm of
the trial is shown in Figure 1. A total of 20 947 eligible household
contacts were identiﬁed. Reasons for exclusion were steroid use
(n = 9), pregnancy (n = 241), liver disease or jaundice (n = 70),
malignancies (n = 7), history of or under treatment for TB (n = 122),
history of leprosy (n = 462), leprosy patient or suspect at intake
(n = 228), refusal of informed consent (n = 1136), under 5 years old
(n = 1900), residing temporarily in the area (n = 1314), or suffering
from another serious illness (n = 673). Some contacts were
excluded because they had more than one exclusion criterion.
HIV was not tested within the trial, but when reported, was used as
an exclusion criterion. After exclusion, 14 988 contacts entered the
trial.
The contacts in both arms of the trial were well-balanced
(Table 2). Of the 14 988 contacts included, 7245 contacts in the
SDR  arm were checked at FU1, 7033 at FU2, and 6898 at FU3
(Figure 1). A total of 7322 contacts in the SDR + arm received SDR at
FU1; 7042 were checked at FU2 and 6906 at FU3. Of the 7322
contacts randomized to receive SDR, 283 did not receive it for
various reasons. These contacts were not included in the effect
calculations.
Among the included contacts, 27 new leprosy patients were
found in the ﬁrst year (at FU2) in the SDR  arm, and 19 in the
SDR + arm. Subsequently, 24 new patients were found in the
second year (at FU3) in the SDR  arm, and 29 in the SDR + arm
(Tables 3–5). The IR of leprosy per 10 000 PYAR was 44 in the
SDR  arm and 31 in the SDR + arm at 1 year, and 34 in the
SDR  arm and 41 in the SDR + arm at 2 years. The reduction in
incidence of leprosy in the SDR + group compared to the SDR 
group was 42% (95% CI  13% to 70%); Rao–Scott Chi-square = 2.1
(df = 1), p = 0.148. The overall NNT was 714 (95% CI 2000 to 313)
for PB leprosy in the ﬁrst year. The reduction in new PB leprosy
cases in the BCG + SDR group occurred in the ﬁrst year after
treatment; in year 2, no statistically signiﬁcant difference in the
number of new PB leprosy cases was found between the groups.
Supplementary Material Tables S1 and S2 show the effect of
BCG only and BCG with SDR prophylaxis by variable category 1 and
2 years after BCG vaccination. No signiﬁcant differences of interest
were found. A negative NNT indicates a statistically non-signiﬁcant
difference.
Table 6 shows the number of new cases at the different follow-
up points including FU1 at 8–12 weeks after BCG. This table shows
that 50 out of a total of 149 new cases (33.6%) occurred within 3
months after BCG vaccination. All except one of these were PB
leprosy cases. Later in the trial, more MB cases arose (eight MB
cases after 1 year and six after 2 years).
The rate of documented adverse events after BCG in the trial
was low (0.34%) and comparable to rates reported in studies from
other countries (Krysztopa-Grzybowska et al., 2012; Dourado et al.,
2003; Turnbull et al., 2002; Grange, 1998). These complications
consisted primarily (80%) of skin ulcerations, which are known,
common and benign adverse events after BCG vaccination; we
have described these previously (Richardus et al., 2018). Except for
the orange urine discolouration caused by rifampicin, no adverse
events were reported after SDR.
Discussion
In the ﬁrst year after the provision of SDR to contacts who had
ﬁrst received BCG vaccination, the number of PB leprosy patients
Table 3
Analysis of all cases of leprosy in contacts of patients with newly diagnosed leprosy.a
Treatment Leprosy No leprosy Total number at risk Incidence rate per 10 000 PYAR 95% CI
BCG
1 year FU 27 7250 7277 44 30–64
2 year FU 24 7118 7142 34 23–50
1–2 years FU 51
BCG and SDR
1 year FU 19 7228 7247 31 20–48
2 year FU 29 7087 7116 41 28–59
1–2 years FU 48
PYAR, person-years at risk; CI, conﬁdence interval; BCG, bacillus Calmette–Guérin; SDR, single dose of rifampicin; FU, follow-up.
a Numbers are provided by treatment arm at 1 and 2 years of follow-up, with incidence rates per 10 000 PYAR (95% CI).
Table 2
Baseline characteristics at intake of contacts of newly diagnosed leprosy patients (N = 14 988) by treatment allocation.a
Variable BCG (n = 7379) % BCG and SDR (n = 7609) % p-Value
Age at intake (in years)
5–14 2203 29.85 2302 30.25 0.68
15–29 2051 27.80 2113 27.77
30–44 1586 21.49 1610 21.16
45 1539 20.86 1584 20.82
Sex
Male 3358 45.51 3407 44.78 0.27
Female 4021 54.49 4202 55.22
Genetic distance to index patient
Blood-related 1662 22.52 1647 21.65 0.34
Not blood-related (or unclear) 5717 77.48 5962 78.35
Type of leprosy in index patient
Paucibacillary 5009 67.88 5367 70.53 0.31
Multibacillary 2370 32.12 2242 29.47
BCG scar
Present 4201 56.93 4369 57.42 0.67
Absent 3172 42.99 3236 42.53
Unknown 6 0.08 4 0.05
Physical distance to index patient
Household contact 2192 29.71 2117 27.82 0.09
Neighbour 5187 70.29 5492 72.18
BCG, bacillus Calmette–Guérin; SDR, single dose of rifampicin.
a Values are numbers and percentages of total numbers of contacts.
Table 5
Analysis of MB leprosy in contacts of patients with newly diagnosed leprosy.a
Treatment MB No leprosy Total number at risk Incidence rate per 10 000 PYAR 95% CI
BCG
1 year FU 3 7274 7277 4.9 1.6–15
2 year FU 0 7142 7142 0.00 –
1–2 years FU 3
BCG and SDR
1 year FU 5 7242 7247 8.1 3.4–20
2 year FU 6 7110 7116 8.4 3.8–19
1–2 years FU 11
MB, multibacillary; PYAR, person-years at risk; CI, conﬁdence interval; BCG, bacillus Calmette–Guérin; SDR, single dose of rifampicin; FU, follow-up.
a Numbers are provided by treatment arm at 1 and 2 years of follow-up, with incidence rates per 10 000 person-years at risk (95% conﬁdence interval).
Table 4
Analysis of PB leprosy in contacts of patients with newly diagnosed leprosy.a
Treatment PB leprosy No leprosy Total number at risk Incidence rate per 10 000 PYAR 95% CI
BCG
1 year FU 24 7253 7277 39b 26–58
2 year FU 24 7118 7142 34 23–50
1–2 years FU 48
BCG and SDR
1 year FU 14 7233 7247 23b 13–38
2 year FU 23 7093 7116 32 22–49
1–2 years FU 37
PB, paucibacillary; PYAR, person-years at risk; CI, conﬁdence interval; BCG, bacillus Calmette–Guérin; SDR, single dose of rifampicin; FU, follow-up.
a Numbers are provided by treatment arm at 1 and 2 years of follow-up, with incidence rates per 10 000 person-years at risk (95% conﬁdence interval).
b Overall reduction in incidence of PB leprosy in the SDR+ group in year 1: 42% (95% CI 13% to 70%); Rao–Scott Chi-square = 2.1 (df = 1), p = 0.148; overall number needed to
treat = 714 (95% CI 2000 to 313).
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Table 6
New leprosy cases among contacts of newly diagnosed leprosy cases identiﬁed
according to the time points of diagnosis.
8–12 weeks 1 year 2 years Total
BCG
PB 23 24 24 71
MB 0 3a 0 3
BCG and SDR
PB 26 14 23 63
MB 1 5 6 12
Total 50 46 53 149
BCG, bacillus Calmette–Guérin; PB, paucibacillary; MB, multibacillary; SDR, single
dose of rifampicin; BI, bacterial index; BL, borderline lepromatous; BT, borderline
tuberculous.
a Only one new MB leprosy case had a BI of 2+ (BL); the rest of the MB cases were
smear-negative (MB BT).
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SDR. No additional effect of SDR was seen in the second year. A
large proportion (33.6%) appeared within 8–12 weeks after
vaccination, the window period between vaccination and the
provision of SDR.
By providing rifampicin (a bactericidal drug) at 8–12 weeks
after BCG vaccination, we envisaged the prevention of new leprosy
cases among contacts in the ﬁrst year after BCG vaccination. This
was described in Brazil by Duppre et al. (2008), who showed that
the risk of PB leprosy was high during the initial months among
those contacts vaccinated with BCG: among the 58 new cases
detected during 18 years of contact follow-up, leprosy was
diagnosed in 21 of these contacts (36%) relatively soon after
vaccination (2–10 months); 18 out of these 21 contacts had PB
leprosy. We also found an unexpectedly high proportion of new PB
leprosy cases following BCG vaccination; however, this phenome-
non had already occurred in the period between BCG vaccination
and SDR provision. This time interval was selected in order to
ensure that rifampicin would not affect the efﬁcacy of BCG, which
is a live vaccine. At the time of conceptualization of the trial, we
had no indication to expect that this would occur this early after
BCG. Most trials have only included long-term follow-up, often
starting 1 year after vaccination. The Brazilian trial (Duppre et al.
(2008)) diagnosed the new leprosy cases 2–10 months after BCG
vaccination, which was also later than what was found in our trial.
In previous studies, either the number of cases was too low to
conﬁrm early ‘induction’ of leprosy after BCG (Karonga Prevention
Trial Group, 1996; HW W, 1960), or it was not speciﬁed when
exactly leprosy occurred after vaccination (Lwin et al., 1985;
Bagshawe et al., 1989). So, at the time SDR was provided in the
current study, most excess cases had probably already become
manifest.
What would have been the result of the trial if SDR had been
given before BCG vaccination? There was no published evidence to
support our decision on the order of BCG and SDR. We simply
followed the logic of the primary research question regarding
whether SDR would suppress the excess cases after BCG
vaccination and designed the study in that order. Also, the
intervention strategy considered the bactericidal effect of SDR on
live bacteria such as BCG. In hindsight, it may have been preferable
to ﬁrst provide SDR, and this should be explored in a future study.
The level of protection offered by SDR in the present study was
42%, which is less than the level reported in the COLEP study (57%)
conducted 10 years previously in the same population (Moet et al.,
2008b). However, our contact population only included household
and ﬁrst neighbour contacts, while the COLEP study also included
second neighbours and social contacts. The further contacts are
physically removed from the index case, the more pronounced is
the effect of SDR in protecting against leprosy. This is probably due
to a lower exposure rate and hence a lower bacterial load of thesefurther distanced contacts, rendering a single dose of rifampicin
more effective (Moet et al., 2008b; Feenstra et al., 2012).
Immunological screening of the effect of SDR on M. leprae infection
in contacts could provide insight into the extent, how fast, and how
durable M. leprae infection is reduced by this single dose of
antibiotic.
The observations from this trial give rise to interesting
hypotheses regarding the immunological mechanisms underlying
the effect of BCG vaccination given to contacts of newly diagnosed
leprosy cases. It is possible that BCG accelerates pro-inﬂammatory
T-helper 1 (Th1) immunity to M. leprae antigens, thereby revealing
incipient forms of PB leprosy. Alternatively, BCG vaccination is
also known to induce trained immunity and thereby non-
speciﬁcally activates protective innate responses (Arts et al.,
2018; Kleinnijenhuis et al., 2012). In a previous study (Richardus
et al., 2018), we showed that BCG vaccination induced signiﬁcant
Th1-type immunity (higher levels of interferon gamma) in those
who presented with high local inﬂammation responses, implicat-
ing that efﬁcient protection against M. leprae is dependent on
an adequate Th1 response (Ottenhoff, 2012), although the
concomitant inﬂammation may result in collateral tissue damage
(Geluk, 2018).
This study investigated the effect of BCG with or without SDR in
one highly endemic area in the Indian sub-continent with a speciﬁc
PB:MB ratio (2:1 instead of the usual 1:1 reported worldwide) (van
Hooij et al., 2016; van Hooij et al., 2018; van Hooij et al., 2019), a low
socio-economic status, and speciﬁc demographic, genetic, and
cultural characteristics. Whether BCG would give similar protec-
tion in other areas of the world is questionable. Furthermore, in
Bangladesh the Moscow strain 361 and Tokyo strain 172 are used;
elsewhere, the use of other BCG strains for vaccination could lead
to different results (Fine, 1995; Zhang et al., 2013).
This trial was not designed to establish the protective effect of
BCG against leprosy. It was assumed that this is a given based on
the literature (Merle et al., 2010; Karonga Prevention Trial Group,
1996; Cunha et al., 2008); therefore an arm without BCG was not
included in the trial. However, we doubt that the protective effect
of BCG alone was large in this study. The IR of leprosy at 2 years
among the household contacts and next-door neighbours in the
non-intervention arm in the COLEP study was 39.35 per 10 000
PYAR (Moet et al., 2008b). The IR was 33.72 per 10 000 PYAR in the
BCG-only arm at 2 years in the MALTALEP trial. This implies a 14.3%
reduction in leprosy incidence by BCG vaccination compared to no
intervention. A Brazilian trial (Duppre et al., 2008) showed that the
protection conferred by a booster BCG vaccination was 56% and
was not substantially affected by previous BCG vaccination. More
speciﬁcally, this effect was 83–85% for the indeterminate and MB
forms of leprosy, but a non-signiﬁcant effect of 26% was found for
the PB leprosy forms. This might explain the lack of effect of BCG in
our trial when compared to no intervention; in Bangladesh, most
patients have the PB form of leprosy (Anonymous, 2017a).
In a subgroup analysis (Supplementary Material), we found no
signiﬁcant difference in the development of leprosy between
revaccinated (BCG scar-positive) versus primary vaccinated (BCG
scar-naïve) contacts. In their meta-analysis, Merle et al. (Merle
et al. (2010)) also found no statistical difference in BCG protection
against leprosy between studies in which individuals were vac-
cinated once and studies in which individuals received a booster
vaccination on top of the neonatal vaccination.
There may be better alternatives to BCG vaccination as
immunoprophylaxis in leprosy, with new candidate leprosy
vaccines in the pipeline, such as MIP (Sharma et al., 2005; Kumar,
2017) and LepVax (Duthie et al., 2018). The MIP vaccine has only
been evaluated in Uttar Pradesh, India, with both patients and
contacts vaccinated. The protective efﬁcacy was 68%, 60%, and 28%
after 3, 6, and 9 years, respectively (Sharma et al., 2005). For
R. Richardus et al. / International Journal of Infectious Diseases 88 (2019) 65–72 71LepVax, post-exposure prophylaxis tested in nine-banded arma-
dillos appeared safe, and unlike BCG, it diminished the neurologi-
cal disruptions caused by M. leprae infection (Duthie et al., 2018).
Further trials are needed to investigate these vaccines before they
can be introduced in the ﬁeld.
A strength of this trial is that it was randomized and controlled
and ﬁeld-based. An extensive number of leprosy contacts were
included (n = 14 988). Also, because it was based in a leprosy-
endemic area, implementation was close to clinical ﬁeld practice.
The loss to follow-up was less than 6%, which was lower than
expected. A limitation is that it was not possible to make it double-
blind (placebo was not available), which may have biased the
results. Even when using a harmless dose of a dissimilar vitamin
pill to prevent participants from knowing whether or not they had
been given an intervention, this would not have prevented bias by
the ﬁeld staff, since they would have known the difference. For
instance, the ﬁeld staff may expect and look more closely for signs
and symptoms of leprosy in those who have not received SDR.
Furthermore, a limitation was that intake took longer than
expected and therefore we could not reach the 10 000 contacts
per arm we set out to include, leading to less power and therefore
less statistically signiﬁcant results.
In conclusion, it is difﬁcult to establish the extent to which SDR
suppresses excess leprosy cases among contacts in the year after
BCG vaccination. Based on this study, we cannot recommend BCG
vaccination followed by SDR as a routine intervention in leprosy
control. However, we do advise contact surveys followed by SDR
to eligible contacts of new leprosy cases. Recently, the WHO
included SDR in the guidelines for its leprosy elimination strategy
(Anonymous, 2017b). Implementation studies on the effective-
ness of SDR as leprosy post-exposure prophylaxis (LPEP) are
currently ongoing (Barth-Jaeggi et al., 2016; Steinmann et al.,
2018).
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